This HTML5 document contains 45 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n9http://linked.opendata.cz/resource/drugbank/drug/DB04982/identifier/drugbank/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n12http://linked.opendata.cz/resource/drugbank/drug/DB04982/identifier/chemspider/
n15http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://linked.opendata.cz/resource/drugbank/drug/DB04982/identifier/kegg-compound/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n11http://linked.opendata.cz/resource/drugbank/drug/DB04982/identifier/bindingdb/
n4http://linked.opendata.cz/resource/drugbank/property/
n8http://linked.opendata.cz/resource/drugbank/drug/DB04982/identifier/pubchem-compound/
xsdhhttp://www.w3.org/2001/XMLSchema#
n6http://linked.opendata.cz/resource/drugbank/drug/DB04982/identifier/pubchem-substance/
n7http://linked.opendata.cz/resource/drugbank/drug/DB04982/identifier/kegg-drug/

Statements

Subject Item
n2:DB04982
rdf:type
n3:Drug
n3:description
Talampanel is a substance that is being studied in the treatment of brain tumors and other brain disorders, such as epilepsy and Parkinson disease. It is a type of AMPA receptor antagonist.
n3:generalReferences
# Langan YM, Lucas R, Jewell H, Toublanc N, Schaefer H, Sander JW, Patsalos PN: Talampanel, a new antiepileptic drug: single- and multiple-dose pharmacokinetics and initial 1-week experience in patients with chronic intractable epilepsy. Epilepsia. 2003 Jan;44(1):46-53. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12581229 # Konitsiotis S, Blanchet PJ, Verhagen L, Lamers E, Chase TN: AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology. 2000 Apr 25;54(8):1589-95. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10762498 # Erdo F, Berzsenyi P, Nemet L, Andrasi F: Talampanel improves the functional deficit after transient focal cerebral ischemia in rats. A 30-day follow up study. Brain Res Bull. 2006 Jan 15;68(4):269-76. Epub 2005 Sep 19. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16377432 # Buchwald P, Juhasz A, Bell C, Patfalusi M, Howes J, Bodor N: Unified pharmacogenetics-based parent-metabolite pharmacokinetic model incorporating acetylation polymorphism for talampanel in humans. J Pharmacokinet Pharmacodyn. 2005 Aug;32(3-4):377-400. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16320099 # Belayev L, Alonso OF, Liu Y, Chappell AS, Zhao W, Ginsberg MD, Busto R: Talampanel, a novel noncompetitive AMPA antagonist, is neuroprotective after traumatic brain injury in rats. J Neurotrauma. 2001 Oct;18(10):1031-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11686490
n3:group
investigational
n3:halfLife
3-6 hours
n3:indication
For the treatment of epilepsy.
owl:sameAs
n15:DB04982
dcterms:title
Talampanel
adms:identifier
n6:10255482 n7:D02696 n8:164509 n9:DB04982 n10:C13670 n11:50173337 n12:144217
n3:mechanismOfAction
Talampanel is a potent noncompetitive and selective antagonist of the glutamine AMPA receptors. Studies in primates have shown that the administration of talampanel to parkinsonian monkeys significantly decreased levodopa-induced dyskinesias by 40%. When given alone, talampanel did not modify the severity of parkinsonian symptoms. However, in combination with levodopa, talampanel potentiated the antiparkinsonian action of levodopa by increasing motor activity.
n3:IUPAC-Name
n4:271B61DD-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B61E3-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B61E2-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B61DF-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B61E0-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B61E1-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B61DB-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B61D9-363D-11E5-9242-09173F13E4C5 n4:271B61DC-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B61DA-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B61E9-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B61EA-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B61E4-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B61E5-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B61E7-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B61E6-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B61E8-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapidly absorbed, with maximal plasma concentrations achieved within 1-3 hours.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
161832-65-1
n3:category
n3:Bioavailability
n4:271B61EE-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B61F0-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B61F1-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B61ED-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B61EC-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B61EF-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B61DE-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B61EB-363D-11E5-9242-09173F13E4C5